edg-5506

Edgewise Therapeutics Announces Positive Two-Year Topline Results from ARCH Study of EDG-5506

Edgewise Therapeutics, Inc., has announced positive two-year topline results from the ARCH open label study of sevasemten (EDG-5506) in adults with Becker. Sevasemten is an orally administered small molecule inhibitor designed to prevent contraction-induced muscle…

Learn More

October 27, 2023

Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne

Edgewise Therapeutics, Inc. has announced an expansion of their clinical development program of EDG-5506. EDG-5506, which comes in the form of a small pill, is an investigational product that aims to protect muscles, specifically fast-twitch…

Learn More

October 24, 2023

WATCH: Edgewise Therapeutics: A Novel Approach Designed to Protect Muscle in Becker (Webinar Recording)

Edgewise Therapeutics joined PPMD for a community webinar on October 18, 2023 to discuss the company’s investigational compound, EDG-5506. Joanne M. Donovan, M.D., Ph.D., Chief Medical Officer at Edgewise, and Alan Russell, Ph.D., Edgewise’s Co-Founder and…

Learn More

September 26, 2023

Edgewise Therapeutics Now Enrolling GRAND CANYON Study of EDG-5506 in Individuals with Becker Muscular Dystrophy

Edgewise Therapeutics has announced the start of enrollment of GRAND CANYON, the company’s global pivotal study of EDG-5506 in individuals with Becker. GRAND CANYON is an expansion of the CANYON study, which was over-enrolled. EDG-5506…

Learn More

Edgewise Therapeutics announces positive topline 12-month data from EDG-5506 ARCH study

Edgewise Therapeutics today announced topline 12-month data from the ARCH study of EDG-5506, an orally administered small molecule designed to prevent contraction-induced muscle damage in patients with Becker muscular dystrophy. The ARCH study is evaluating…

Learn More

WATCH: Edgewise — A Novel Approach Designed to Protect Muscle in Becker (Webinar Recording)

PPMD was joined by Edgewise Therapeutics for a community webinar on May 3, 2023 to discuss the company’s novel approach designed to protect muscle in individuals living with Becker muscular dystrophy. The webinar highlighted EDG-5506,…

Learn More

October 21, 2022

WATCH: Edgewise Therapeutics – A Novel Approach to Protect Muscle in Duchenne & Becker (Webinar Recording)

PPMD was joined by Edgewise Therapeutics for a community webinar on October 19, 2022. Edgewise’s Chief Scientific Officer and Chief Medical Officer discussed the clinical development program for EDG-5506, a myosin modulator, in Becker and…

Learn More

October 18, 2022

Edgewise Announces 6 Sites Enrolling for CANYON, Phase 2 Trial of EDG-5506 in Becker

Edgewise has shared a community letter announcing that six sites are now open for enrollment for the Canyon trial for individuals living with Becker muscular dystrophy. Canyon is a Phase 2 trial of EDG-5506, a…

Learn More

September 12, 2022

Edgewise Announces 4-Month Interim Results from ARCH Open Label Study of EDG-5506 in Adults with Becker

Edgewise Therapeutics has released 4-month interim results from the ongoing ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy. EDG-5506 is a small molecule, taken orally, that is intended to help protect muscle…

Learn More

September 7, 2022

Edgewise Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 in Participants with Duchenne

Edgewise Therapeutics has announced the FDA has authorized the initiation of the LYNX Phase 2 clinical trial of EDG-5506 in participants with Duchenne. EDG-5506 is a small molecule, taken orally, that is intended to help protect muscle by reducing…

Learn More

Join Our Mailing List